Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday but nudged up its sales outlook for this year on the back of its new drugs for type 2 diabetes and obesity.
The world’s largest maker of diabetes drugs posted a quarterly operating profit of 12.9 billion Danish crowns ($1.93 billion), slightly below an average 13.1 billion crowns forecast in a Refinitiv poll of analysts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.